Women of childbearing potential (<  year amenorrheic) or sexually active males who are not employing adequate contraception (or practicing complete abstinence); female patients of childbearing potential must commit to using a reliable and appropriate method of contraception until at least  months after the end of last dose of study treatment; male patients with a partner of childbearing potential must agree to use a barrier method of contraception (condom) in addition to having their partner use another contraceptive method during the trial and for  months after the last dose of study treatment; examples of reliable and appropriate methods of contraception include hormonal implants, oral contraceptives, intra-uterine devices, or a barrier method used in conjunction with spermicidal jelly
Patients of childbearing potential must agree to use an effective form of contraception during this study and for  days following the last dose of chemotherapy; an effective form of contraception is an oral contraceptive or a double barrier method
Male patients should be willing to use barrier contraception (i.e. condoms)
Subjects and their partners with reproductive potential must agree to use effective contraceptive measures during the study and for  months after the last dose of study treatment. Effective contraception includes methods such as oral contraceptives or double-barrier method (eg, use of a condom AND diaphragm, with spermicide).
Of child-bearing potential, Subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device from the time of signing the informed consent through at least  weeks after the last dose of study drug. Female subjects must have a negative serum or urine pregnancy test within  hours prior to start of trial medication.
Females must be postmenopausal (> months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or, if sexually active, must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for  days after their last dose of study drug.
If female of child-bearing potential (i.e. not postmenopausal or surgically sterile), must be willing to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods. If male, must be sterile or willing to abstain from sexual intercourse or employ a barrier method of contraception during the study treatment and follow-up periods.
Subject agrees to use a double barrier method of birth control during the course of study treatment period with enzalutamide and/or cabazitaxel treatment and for at least  months after the study is discontinued\r\n* A double-barrier method of contraception involves the use of a condom in combination with  of the following: contraceptive sponge, diaphragm, or cervical ring with spermicidal gel or foam\r\n* Subject who has had a vasectomy at least  months prior to starting study treatment period and those whose female sexual partner(s) are more than  years of age and postmenopausal for at least  years or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) agree to use at least a condom
Men whose sexual partners are women of childbearing potential not using a double method of contraception during the study and  months after the end of treatment; one of these methods must be a condom
If female of child-bearing potential (i.e. not postmenopausal or surgically sterile), must be willing to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and for at least  months following last treatment. If male, must be sterile or willing to abstain from sexual intercourse or employ a barrier method of contraception during the study treatment and for at least  months following last treatment.
Male patients: Willing to use adequate contraception (barrier or abstinence) while on treatment with study drug and for  months after finishing treatment
Female patients: Willing to use adequate contraception (barrier or abstinence) while on treatment with study drug and for  months after finishing treatment
Male patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for  months after treatment stops
Male patients should be willing to use barrier contraception (i.e., condoms).
IUD plus one barrier method;
Stable doses of hormonal contraception for at least  months (e.g., oral, injectable, implant, transdermal) plus one barrier method;
Male patients should be willing to use barrier contraception for the duration of the study and for  months after treatment discontinuation. Inclusion Criteria for Phase b Expansion Cohorts
Woman must be postmenopausal (>  months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for  days after their last dose of IP.
Female subjects must not be pregnant or at risk to become pregnant during the study. Fertile male and female subjects must agree to use an effective barrier method of birth control to avoid pregnancy (for female subjects a double-barrier method of contraception, for male subjects a condom with spermicide) or total abstinence from the time of providing informed consent until  days after the last administration of study drug. Use of oral contraceptives is not allowed.
All females of childbearing potential must use an effective barrier method of contraception (either an intrauterine device contraceptive [IUDC] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least  month thereafter; male subjects should use a barrier method of contraception during the treatment period and for at least  months thereafter; female subjects should avoid the use of estrogen-containing contraceptives
PART I: Willingness of female and male subjects to use effective contraception e.g. oral contraceptives, barrier device, intrauterine device, or condoms, during the study and for three months following the last dose of study vaccine; suggested that subjects do not become pregnant or father a child during the study, and for  months following receipt of the investigational AdHER dendritic cell (DC) vaccine
PART II: Willingness of female subjects to use effective contraception e.g. oral contraceptives, barrier device, intrauterine device, or condoms, during the study and for three months following the last dose of study vaccine; we suggest that subjects do not become pregnant during the study, and for  months following receipt of the investigational AdHER DC vaccine
Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including  days after the last dose of study drug. Sperm donation is prohibited during the study and for  days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent
Male subjects must be willing to use barrier contraception
Male patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for  weeks after the last dose of study treatments
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for  months after discontinuation of vemurafenib
Women of childbearing potential or men who is unwilling to use an appropriate method of contraception during the study period and for  months after completing treatment with Debio ; oral or injectable contraceptive agents cannot be the sole method of contraception
Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least  consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.
Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through  weeks ( months) after the last dose of study therapy
Patient must be willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least  days after study treatment. Patients surgically sterilized or who are postmenopausal for at least  year (defined as more than  months since last menses) do not require contraception.
Patients of reproductive potential must use effective contraception for the duration of the study and for  months ( days) after the last administered injection of OBP-. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device.
All women of childbearing potential must agree to use an effective barrier method of contraception during the treatment period and for at least  month after discontinuation of the study drug; male subjects should use effective barrier method of contraception during the treatment period and for at least  month after discontinuation of the study drug
Negative urine or serum pregnancy test for women of childbearing potential; all women of childbearing potential must agree to use an effective barrier method of contraception (either an intrauterine device [IUD] or double-barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least  month after discontinuation of the study drugs; male subjects should use effective barrier method of contraception during the treatment period and for at least  months after discontinuation of the study drugs
Male patients must use a form of barrier contraception approved by the investigator during the study and for  months after the last dose of study drug;
Women of child-bearing potential must agree and commit to use of a highly effective double-barrier method of contraception (e.g., a combination of male condom with an intravaginal device such as the cervical cap, diaphragm, or vaginal sponge with spermicide) or a non-hormonal method, from the signing of informed consent until  days after the last dose of neratinib and  months after the last dose of trastuzumab, or consent to total sexual abstinence (abstinence must occur from randomization and continue for  days after the last dose of neratinib and  months after the last dose of trastuzumab); men without confirmed vasectomy must agree and commit to use a barrier method of contraception while on treatment and for  months after the last dose of investigational products, or consent to total sexual abstinence (abstinence must occur from randomization and continue for  months after the last dose of study medication)
For women who are not postmenopausal ( months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception; for men: agreement to use a barrier method of contraception during the treatment period
All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device [IUD]) with their partner from entry into the study through three months after the last dose
Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including  days after the last dose of study drug; sperm donation is prohibited during the study and for  days after the last dose of study drug; female partners must use hormonal or barrier contraception unless postmenopausal or abstinent
For the duration of the study and for  week after the last study drug administration, sexually active male patients must be willing to use barrier contraception i.e., condoms with all sexual partners
CELL PROCUREMENT: Females and males of childbearing potential must be willing to abstain from heterosexual activity or to use  forms of effective methods of contraception from the time of informed consent until  months after treatment discontinuation; the two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method; female participants will inform their male partners that they must use the methods of birth control required by the protocol\r\n* Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through  months after the last dose of study therapy
LYMPHODEPLETION: Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through  months after the last dose of study therapy
iC-CAR CELL INFUSION: Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through  months after the last dose of study therapy
All patients must agree to use barrier contraception (i.e. condom) during study treatment and for  months after the last virus treatment and  months after the last dose of chemotherapy and pembrolizumab.
Women must be postmenopausal (> months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for  days after their last dose of study drug
For women of childbearing potential using a contraceptive pill, an additional barrier method is necessary. A list of adequate contraception methods is provided in the patient information.
Male patients must be willing to use barrier contraception (i.e., condoms) for the duration of the trial and for  months after trial treatment discontinuation.
Male patients who are not surgically sterile unless they are using a double barrier contraception method from enrollment through treatment and for  months following administration of the last dose of study drug
Female subjects may be enrolled in the trial if they are: \r\n* of non-childbearing potential which is defined as: \r\n* of childbearing potential who are willing to use either  adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy, or to abstain from heterosexual activity throughout the trial, starting with the screening visit (visit ) through  days after the last dose of MK- (pembrolizumab)
Negative urine or serum pregnancy test for females of childbearing potential; all females of childbearing potential must use an effective barrier method of contraception (either an intrauterine device [IUD] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least  month thereafter; male subjects should use a barrier method of contraception during the treatment period and for at least  months thereafter
Pre-menopausal patients must have a negative pregnancy test and agree to use birth control methods while participating in the study; women of childbearing age and their male counterparts should use a barrier method of contraception during and for  months following protocol therapy
Male patients must be willing to use an appropriate method of contraception (e.g., condoms) or abstain from sexual intercourse and inform any sexual partners that they must also use a reliable method of contraception during the study and for  days after dosing.
Men of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < % during and for  months after discontinuation of study treatment\r\n* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur
Sexually active patients of childbearing potential must be willing to use an acceptable method of contraception such as an intrauterine device or double barrier contraception during treatment and for  days after the last dose of study drug (hormonal contraception is not allowed)
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for  months after discontinuation of MK-
All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through  months after the last dose of chemotherapy
All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device [IUD]) with their partner from entry into the study through  months after the last dose
Men must be willing not to father a new child while receiving therapy; they must use an effective barrier method of contraception during the study and for  months following the last dose
Condom (barrier method of contraception) AND
Male patients must be surgically sterile or use double barrier contraception method from enrollment through treatment and for  months following administration of the last dose of study drug.
For male patients with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for  months from receiving the last dose of IP
Able and willing to use double barrier method of contraception for at least  months prior to ST- infusion and through  months post-transplant
Male patients should be willing to use barrier contraception
If female, must be either postmenopausal, sterilised or, if sexually active, effectively practicing an acceptable method of contraception (either oral, parenteral, or implantable hormonal contraceptives, intrauterine device or barrier and spermicide). Subjects must agree to use adequate contraception during the study and for at least  weeks (or longer as per local requirement) after the last dose of study treatment.
During the study and for at least  days after receiving the last dose of study drug, in addition to the highly effective method of contraception, a man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (example [eg.], condom with spermicidal foam/gel/film/cream/suppository), or who is sexually active with a woman who is pregnant must use a condom
The effects of AR- on the developing human fetus at the recommended therapeutic dose are unknown. For this reason women of child-bearing potential (i.e., not post-menopausal for at least  months and not surgically sterile) and men must agree to use effective methods of contraception. Women of childbearing potential (any women who is not surgically sterile or >  years post menopause) must give consent for using a reliable method of contraception (e.g. double-barrier, tubal ligation or stable hormonal contraception) throughout the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
In women who have not experienced menopause, negative pregnancy test prior to initiation of treatment and adequate contraception throughout treatment. Adequate forms of contraception include:\r\n*  adequate barrier methods\r\n* A barrier method plus a hormonal method of contraception\r\n* Abstaining from sexual activity throughout the trial, starting with the screening visit through  days after the last dose of pembrolizumab.
Willingness of male and female patients, if sexually active, to use an effective barrier method of contraception during the study and for  months following the last dose of study drug
Female subject is post-menopausal (no menstrual period for a minimum of  months) or surgically sterilized and has a negative serum pregnancy test upon entry. Women of childbearing potential (WOCBP) must use an oral or implanted contraceptive, a double barrier method of birth control or an intrauterine device upon enrollment through  months after receiving the last dose of IP. Male subject is surgically sterile or is willing to use contraception upon enrollment through  months after receiving the last dose of IP.
Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through  months after the last dose of study therapy
Males and females of child-bearing potential*, willing to use an effective form of contraception during chemotherapy treatment and for at least  months thereafter. Such methods include: (if using hormonal contraception this method must be supplemented with a barrier method, preferably male condom)
ARM A: The patient and their partner agree to use a barrier method of contraception during the study and  months following end of active treatment
ARM B: The patient and their partner agree to use a barrier method of contraception during the study and  months following end of active treatment
Subjects must use  forms of highly effective contraception concomitantly from the initiation of study therapy until  months after the last dose of study therapy; additionally, the use of condoms is required; it should also be noted that, where  forms of effective contraception are required, a subject may choose to use a double-barrier method consisting of condom and cervical occlusive cap / diaphragm with spermicide
Male patients must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for  month following the last study drug infusion
All sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for  days following their last dose of study treatment. WOCBP and males whose sexual partners are WOCBP agree to use barrier contraception and a second form of contraception while receiving study treatment and for  days following their last dose of study treatment.
Condom (barrier method of contraception), and . One of the following:
A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study
For male patients who are sexually active and who are partners of premenopausal women: agreement to use a barrier method of contraception during the treatment period and for at least  months after the last dose of study drug.
If female, is post-menopausal, surgically sterilized or willing to use an effective method of contraception for the duration of the study and for  months after the end of treatment. If male, has agreed to use barrier method for contraception for the duration of the study and for  months after the end of treatment.
use an effective barrier method of contraception
Male patients should be willing to use barrier contraception, i.e., condoms, until  months after last study drug is taken.
Subjects and their partners of reproductive potential must agree to use an effective form of contraception during the period of drug administration and for four weeks following the completion of the last administration of the study drug; an effective form of contraception is defined as oral contraceptives plus one form of barrier method or double barrier methods (condom with spermicide or condom with diaphragm)
All participants must agree to use double barrier contraception during study participation and for at least  months after the last dose of study drug.
Willing to use double-barrier contraception if sexually active and not surgically sterilized (female only)
Patient must be willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least  days after the last dose of the study drug.
Condom (barrier method of contraception); AND
Women of child-bearing potential (not free from menses for >  years, post hysterectomy/oophorectomy, or surgically sterilized) must agree to use two methods of contraception, or abstain from heterosexual activity, during participation in study, from the time of consent through  days after the last dose of study therapy; the two methods must include at least one barrier method. Barrier methods are diaphragms, cervical caps, cervical shields, male condoms, and female condoms; the second method of contraception may be another barrier method, a copper containing intrauterine device (IUD), spermicidal foams, sponges and films, or hormone-based contraception (for example, hormone pills, hormone rings, hormone patches, hormone-releasing IUDs, or Depo Provera); men with partners who are capable of getting pregnant must agree to use one of  the barrier methods of contraception listed above during participation in the study, starting with the first dose of study drug through  days after the last dose of study therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device [IUD]) with their partner from entry into the study through  months after the last dose
Male patients should be willing to use barrier contraception, i.e. condoms.
Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least  consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent; adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence
Sexually active patients must be willing to use an acceptable method of contraception such as double barrier contraception during treatment and for  months after the last dose of BMN 
If not surgically sterile, male and female patients of childbearing age must use double barrier contraception (hormonal; intrauterine device; barrier)
Male patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign the ICF) and for  months after the last dose of vandetanib to prevent pregnancy in a partner
All females of childbearing potential must use an effective barrier method of contraception (either an intrauterine contraceptive device [IUDC] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least  month thereafter; male subjects should use a barrier method of contraception during the treatment period and for at least  months thereafter; female subjects should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives
Patient agrees to use an effective method of contraception (hormonal or two barrier methods) while on study and for at least  months following the plerixafor infusion
Condom (barrier method of contraception), AND
Patients of both sexes must agree to the use of barrier contraceptives throughout the duration of treatment on this trial and for  months after discontinuing treatment; NOTE: hormonal contraceptives are not acceptable as a sole method of contraception
Male patients should be willing to use barrier contraception.
A patient who is sexually active and their partner must agree and use two reliable barrier forms of contraception (for example, condoms and diaphragm), from first day of study drug administration until for  week after last dose of abiraterone acetate, unless partner is post-menopausal
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for  months after discontinuation of vemurafenib
Subject not consenting to the use of highly effective contraceptive precautions (e.g., double barrier method [i.e., condom plus diaphragm]) during the course of the study and for  months after administration of the last study medication
Female patients must be of non child-bearing potential or use effective contraception, e.g., use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, total abstinence, and willing to continue the effective contraception method for  days after the last dose of AVX
Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with Female of Childbearing Potential as specified in Pregnancy Prevention Risk Minimization Plan.
Condom (barrier method of contraception) AND
If female and of childbearing potential, or if male, agree to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until  weeks after the last dose of study drug.
If the subject is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for  days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method).
Subjects and their partners with reproductive potential must agree to use an effective form of contraception during the period of drug administration and for  weeks after completion of the last administration of the study drug; an effective form of contraception is defined as oral contraceptives plus  form of barrier or double-barrier method contraception (condom with spermicide or condom with diaphragm)
For patients of childbearing potential, agreement to use two effective forms of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study and for  days after the last LY dose
Subjects and their partners with reproductive potential must agree to use an effective form of contraception during the period of drug administration and for  weeks after completion of the last administration of the study drug, an effective form of contraception is defined as oral contraceptives plus  form of barrier or double-barrier method contraception (condom with spermicide or condom with diaphragm)
Males (including those who have had a vasectomy) must practice complete abstinence or use barrier contraception (condoms) when engaging in sexual activity with FCBP as specified in the PPRMP.
Female patients of childbearing potential (not surgically sterile) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
Patient with reproductive potential (female and male) who do not agree to use an accepted effective method of contraception (hormonal or barrier methods, abstinence) during the study treatment period and for at least  months following completion of study treatment; for female patient enrolled, the following methods of contraception are acceptable: oral contraceptives accompanied by the use of a second method of contraception, or intra uterine device (IUD) or women who are surgically sterile, or women who are post menopausal or other reasons have no chance of becoming pregnant
Use of two forms of contraception with less than a % failure rate or abstinence by all transplanted participants for  months after the first dose of study therapy; for the first  days post-transplant, recipients should be encouraged to use non-hormonal contraceptives; if using a barrier method, a double barrier method should be used
Unwillingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods.
Women of childbearing potential must commit to using a double barrier method of contraception, an intrauterine device, or sexual abstinence for the duration of the study and for at least three months after study completion
For women who are not postmenopausal or surgically sterile; agreement to use an adequate method of contraception (hormonal implant) during the treatment period and for at least  days after the last dose of onartuzumab/placebo and  months after the last dose of oxaliplatin
For men: agreement to use a barrier method of contraception during the treatment period and for  days after the last dose of onartuzumab/placebo and  months after the last dose of oxaliplatin
Agree to use a double-barrier method of contraception which involves the use of a condom in combination with one of the following: contraceptive sponge, diaphragm, or cervical ring with spermicidal gel or foam, if having sex with a woman of child-bearing potential during the length of the study and for one week after abiraterone is discontinued and for at least three months after enzalutamide is discontinued
Unwillingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods.
Male patients must use an effective barrier method of contraception during study and for  months following the last dose if sexually active with a FCBP.
Female participants must be postmenopausal (no spontaneous menses for at least  years), surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the investigator), or if sexually active, be practicing an effective method of birth control. Male participants must agree to use an adequate contraception method as deemed appropriate by the investigator (e.g., vasectomy, double-barrier, partner using effective contraception) and to not donate sperm for a minimum of  months after treatment discontinuation Optional Extension Phase (OEP) Phase:
Men engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence while on study drug and for  months after discontinuation from study drug
Female patients must be one year post-menopausal, surgically sterile, or using an acceptable method of contraception during and continued after the last dose of study medications (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation); male patients must be surgically sterile or using an acceptable method of contraception during their participation in this study; contraceptive use will continue for at least two months after the last dose of study medication
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within  days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method or abstain from sexual activity during the study and for  months after last study drug administration; sexually active males and their female partners must agree to use two methods of accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study
Use of an effective means of contraception (e.g., abstinence, hormonal or double barrier method, surgically sterilized partner) for men and women of childbearing potential while enrolled in the study
If a female of childbearing potential, must have a negative serum pregnancy test within  days of the first dose of abemaciclib and agree to use a medically approved contraceptive method during the treatment period and for  months following the last dose of abemaciclib; if a male, agree to use a reliable method of birth control and to not donate sperm during the treatment period and for at least  months following the last dose of abemaciclib; contraceptive methods may include an intrauterine device (IUD) or barrier method; if condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection\r\n* Note: cases of pregnancy that occur during maternal exposures to abemaciclib should be reported; if a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately; data on fetal outcome and breast-feeding are collected for regulatory reporting and drug safety evaluation
Are using oral hormonal contraceptives and who do not agree to add a barrier method
Men of reproductive potential and those who are surgically sterilized (i.e., post vasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < % during and for  days after discontinuation of study treatment\r\n* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur
Pregnant, unwilling to use adequate contraception during study treatment duration, had given birth, or nursed at any time during the last  months\r\n* All heterosexually active women who may become pregnant must agree to use a reliable nonhormonal contraceptive method during the study and for  months after completing study medications; reliable nonhormonal methods of contraception include barrier contraception and an intra-uterine device (IUD); [Note: Women who had tubal ligation or had a partner who had undergone a vasectomy (and are monogamous) are eligible for the study and are not required to use barrier contraception
For women who are not postmenopausal ( months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception; for men: agreement to use a barrier method of contraception during the treatment period
Using an adequate method of contraception for at least  months with no changes and will remain on the contraception for the duration of the trial; an adequate method of contraception is defined as either a hormonal based method (except vaginal rings); an intrauterine device (IUD) (inserted at least  days prior to enrollment); female sterilization; or sexual activity with a partner who had a vasectomy
Willing to use double-barrier protection if sexually active
Women of childbearing potential who are not using a reliable method of contraception; methods of contraception that are considered reliable are intrauterine devices (IUDs), birth control pills, hormonal implants/patches, and barrier contraception when used with spermicidal products; the rhythm method is not considered a reliable method of contraception
For women of childbearing potential, agreement to use an effective form of contraception (patient and/or partner, e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study treatment, and for a minimum of  months following trastuzumab and/or pertuzumab administration
If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter
Women of childbearing potential and men who are able to father a child, must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for  days following the last dose of the study drug.
Subjects of child-bearing potential must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Depo-Provera) during the study and for  days following the last dose of the study drug
Female subjects of childbearing potential and all male subjects are required to consent to use a medically acceptable method of contraception throughout the study period and for  days after amatuximab administration; a barrier method of contraception is required
If of childbearing potential, is willing to abstain for sexual intercourse or to use an effective form of contraception (double-barrier method) during the study and for  days following the last dose of ganetespib
The patient must take precautions to not become pregnant or produce offspring. Women must be of non-childbearing potential (surgically sterile or postmenopausal for at least  months, confirmed by follicle-stimulating hormone [FSH] > IU/L) or agree to use a medically accepted method of contraception for the duration of the study and  days after treatment. Men must be surgically sterile or agree to use a medically accepted method of contraception for the duration of the study and  days after treatment. Acceptable methods of contraception include abstinence, barrier method with spermicide (excluding cervical cap and sponge), intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
Women must be postmenopausal (> months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for  days after their last dose of study drug.
